News >

Nivolumab Plus Low-Dose Ipilimumab Shows Durable Responses for PD-L1-Negative, TMB-High NSCLC

Silas Inman @silasinman
Published: Wednesday, Jun 06, 2018

Hossein Borghaei, DO

Hossein Borghaei, DO, MS

The combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden (TMB)-high non–small cell lung cancer (NSCLC), according to findings from the phase III CheckMate 227 trial presented at the 2018 ASCO Annual Meeting.1

Across all PD-L1­–negative patients (N = 550), the objective response rate (ORR) with the nivolumab/chemotherapy combination was 36.7% compared with 23.1% with chemotherapy alone. The median duration of response was 7.2 versus 4.7 months for the nivolumab/chemotherapy and chemotherapy alone arms, respectively. The ORR with nivolumab plus ipilimumab was 25.1% with a median duration of response was 18.0 months.


At the analysis, 72% of patients continued to respond for ≥1 year in the nivolumab/ipilimumab combination arm. The duration of response was similar between the other groups. Twenty-eight percent of patients receiving nivolumab/chemotherapy responded for ≥1 year compared with 24% for chemotherapy alone.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x